Relationship of betatrophin with youth onset type 2 diabetes among Asian Indians

Gokulakrishnan, Kuppan; Manokaran, Kalaivani; Pandey, Gautam Kumar; Amutha, Anandakumar; Ranjani, Harish; Anjana, Ranjit Mohan; Mohan, Viswanathan

doi:10.1016/j.diabres.2015.04.028

Cited by 26 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data did not find the association between circulating full-length betatrophin level with lipid profiles, transaminases and other parameters, which were suggested by previous reports [17, 31]. In a recent study, urine albumin / creatinine ratio (uACR) was considered to be associated with the circulating betatrophin level [32].…”

Section: Discussioncontrasting

confidence: 77%

Increased circulating full-length betatrophin levels in drug-naïve metabolic syndrome

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Betatrophin is a newly identified circulating adipokine playing a role in the regulation of glucose homeostasis and lipid metabolism. But its role in metabolic syndrome (MetS) remains unknown. Therefore, we aimed to compare the circulating betatrophin concentrations between patients with MetS and healthy controls. We recruited 47 patients with MetS and 47 age and sex matched healthy controls. Anthropometric and biochemical measurements were performed, and serum betatrophin levels were detected by ELISA. Full-length betatrophin levels in patients with MetS were significantly higher than those in controls (694.84 365.51 pg/ml versus 356.64 287.92 pg/ml; P <0.001). While no significant difference of total betatrophin levels was found between the two groups (1.20 0.79 ng/ml versus 1.31 1.08 ng/ml; P = 0.524). Full-length betatrophin level was positively correlated with fasting plasma glucose (FPG) (r = 0.357, P = 0.014) and 2-hour plasma glucose (2hPG) (r = 0.38, P <0.01). Binary logistic regression models indicated that subjects in the tertile of the highest full-length betatrophin level experienced higher odds of having MetS (OR, 8.6; 95% CI 2.8-26.8; P <0.001). Our study showed that full-length betatrophin concentrations were increased in drug-naïve MetS patients.

show abstract

Section: Discussioncontrasting

confidence: 77%

Increased circulating full-length betatrophin levels in drug-naïve metabolic syndrome

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…On one hand subsequent preclinical studies examining the effects of deletion as well as overexpression of betatrophin showed no evidence for a prominent isolated role of betatrophin in controlling beta-cell proliferation[23, 24]. On the other hand the clinical evaluation of betatrophin in humans yielded a quite heterogeneous pattern with partially contradictory results [11, 18, 25, 26]. The recent retraction of the initial paper describing betatrophin as potential beta cell mitogen [27] and the collected data from clinical studies largely invalidate the perspective of a clinically relevant player in beta cell proliferation.…”

Section: Resultsmentioning

confidence: 99%

Renal function is independently associated with circulating betatrophin

et al. 2017

View full text Add to dashboard Cite

ObjectiveBetatrophin has been identified as a marker linking liver with beta cell function and lipid metabolism in murine models. Until now, the regulation of circulating betatrophin in humans is not entirely clear. We here analyzed the relation of betatrophin levels to phenotypes of the metabolic syndrome and speculated that renal function might influence circulating betatrophin levels and explain age-dependent changes of betatrophin.SubjectsWe analyzed blood samples from 535 individuals participating in the Metabolic Syndrome Berlin Potsdam study.ResultsIn a crude analysis we found a positive correlation between betatrophin levels and HbA1c (r = 0.24; p < 0.001), fasting glucose (r = 0.20; p < 0.001) and triglycerides (r = 0.12; p = 0.007). Furthermore betatrophin was positively correlated with age (r = 0.47; p <0.001), systolic blood pressure (r = 0.17; p < 0.001), intima media thickness (r = 0.26; p < 0.001) and negatively correlated with CKD-EPI eGFR (r = -0.33; p < 0.001) as an estimate of renal function. Notably, eGFR remained highly associated with betatrophin after adjustment for age, waist circumference, gender, HbA1c and lipid parameters in a multivariate linear regression model (β = -0.197, p< 0.001).ConclusionsOur data suggest that circulating levels of betatrophin depend on age, gender, waist circumference, total/HDL cholesterol ratio and renal function. Especially the association to eGFR highlights the importance for future studies to address renal function as possible influence on betatrophin regulation and consider eGFR as potential confounder when analyzing the role of betatrophin in humans.

show abstract

“…Although the betatrophin level has been investigated in several studies, the results are inconsistent and inconclusive. Although there is convincing evidence showing increased betatrophin in T2DM and type 1 diabetes, 16 17 18 no elevation in the betatrophin level 12 and even its reduction in youth-onset T2DM 19 and T2DM have also been reported. 20 Considering the literature to date, our observation in Iranian patients with T2DM is in line with recent studies indicating increased betatrophin levels in patients with T2DM and type 1 diabetes.…”

Section: Discussionmentioning

confidence: 99%

Circulating Betatrophin Levels Are Associated with the Lipid Profile in Type 2 Diabetes

et al. 2015

View full text Add to dashboard Cite

Betatrophin is a newly characterized circulating hormone that is produced in tissues such as adipose tissue and liver and stimulates pancreatic beta-cell proliferation. The purpose of the current study was to examine circulating betatrophin levels in Iranian patients with type 2 diabetes mellitus (T2DM) and in normal controls. Seventy-five subjects were enrolled in this case-control study in the following two groups: T2DM patients (n=40) and a group of age-, sex-, and BMI-matched normal control subjects (n=35). Circulating betatrophin concentrations as well as the blood lipid profile, body mass index (BMI), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and insulin resistance were determined. Circulating betatrophin levels were significantly higher in patients with T2DM than in the normal subjects (4.79±1.53 ng/mL vs. 2.79±1.11 ng/mL respectively; p=0.001). Serum triacylglycerol and total cholesterol were also significantly higher in patients with T2DM than in the control group. In the patients with T2DM, serum betatrophin was positively correlated with age, FBS, TG, total cholesterol, and HbA1c. The results of this initial study in Iran have shown that circulating betatrophin levels are significantly increased in Iranian patients with T2DM compared with a control group. Additionally, it is postulated that betatrophin as a novel hormone may be involved in the generation of an atherogenic lipid profile.

show abstract

Relationship of betatrophin with youth onset type 2 diabetes among Asian Indians

Cited by 26 publications

References 43 publications

Increased circulating full-length betatrophin levels in drug-naïve metabolic syndrome

Increased circulating full-length betatrophin levels in drug-naïve metabolic syndrome

Renal function is independently associated with circulating betatrophin

Circulating Betatrophin Levels Are Associated with the Lipid Profile in Type 2 Diabetes

Contact Info

Product

Resources

About